- Home
- BNY vs LYEL Comparison
BNY vs LYEL Comparison
Compare BNY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$33.46
Company Overview
Basic Information| Metric | BNY | LYEL |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.0M | 369.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BNY | LYEL |
|---|---|---|
| Price | $10.17 | $33.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 52.7K | ★ 55.7K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.60 | $7.65 |
| 52 Week High | $10.80 | $35.16 |
Technical Indicators
Market Signals| Indicator | BNY | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 82.35 |
| Support Level | $10.20 | $20.59 |
| Resistance Level | $10.27 | $25.20 |
| Average True Range (ATR) | 0.08 | 2.69 |
| MACD | 0.00 | 1.16 |
| Stochastic Oscillator | 36.96 | 94.50 |
Price Performance
Historical Comparison BNY
LYEL
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.